CATCH T cells for Yolk Sac Tumor

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Yolk Sac Tumor+7 MoreCATCH T cells - Genetic
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to fight cancer by genetically engineering patients' T cells to better target and kill their tumor cells.

Eligible Conditions
  • Solid Tumors
  • Embryonal Sarcoma of the Liver
  • Malignant Rhabdoid Tumor
  • Yolk Sac Tumor
  • Rhabdomyosarcoma
  • Wilms Tumor
  • Liposarcoma
  • Liver Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 15 years

15 years
Median T cell persistence
4 weeks
Number of Patients with Dose Limiting Toxicity
Percent of Patients with best response as either complete remission or partial remission

Trial Safety

Trial Design

1 Treatment Group

CATCH T cells + Fludarabine and Cytoxan
1 of 1

Experimental Treatment

27 Total Participants · 1 Treatment Group

Primary Treatment: CATCH T cells · No Placebo Group · Phase 1

CATCH T cells + Fludarabine and CytoxanExperimental Group · 3 Interventions: Cytoxan, CATCH T cells, Fludara · Intervention Types: Drug, Genetic, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 15 years

Who is running the clinical trial?

The Methodist Hospital Research InstituteOTHER
240 Previous Clinical Trials
35,584 Total Patients Enrolled
Baylor College of MedicineLead Sponsor
923 Previous Clinical Trials
5,988,022 Total Patients Enrolled
2 Trials studying Yolk Sac Tumor
48 Patients Enrolled for Yolk Sac Tumor
Center for Cell and Gene Therapy, Baylor College of MedicineOTHER
108 Previous Clinical Trials
2,759 Total Patients Enrolled
2 Trials studying Yolk Sac Tumor
48 Patients Enrolled for Yolk Sac Tumor
Tannaz Armaghany, MDPrincipal InvestigatorBaylor College of Medicine
3 Previous Clinical Trials
72 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are diagnosed with a GPC3-positive solid tumor, which has either relapsed or is refractory; and immunohistochemistry assessment of the cancer cells shows an extent score greater than Grade 2 (more than 25% positive) and intensity score higher than 2 (scale 0-4).
You are at least 18 years of age.
You have a Lansky or Karnofsky score of at least 60%.
You are expected to live for at least 16 weeks.
You have hepatocellular carcinoma and are classified as Barcelona Clinic Liver Cancer Stage A, B or C.
You have a Child-Pugh-Turcotte score of seven or less, if you are suffering from hepatocellular carcinoma.
Patients/guardians must comprehend the informed consent and sign it, with a copy being provided.